Maraviroc for Previously Treated Patients with R5 HIV-1 Infection
New England Journal of Medicine2008Vol. 359(14), pp. 1429–1441
Citations Over TimeTop 1% of 2008 papers
Roy M. Gulick, Jacob Lalezari, James Goodrich, Nathan Clumeck, Edwin DeJesus, Andrzej Horban, Jeffrey P. Nadler, Bonaventura Clotet, Anders Karlsson, Michael Wohlfeiler, John B Montana, Mary McHale, John F. Sullivan, Caroline E. Ridgway, Steve Felstead, Michael W. Dunne, Elna van der Ryst, Howard Mayer
Abstract
Maraviroc, as compared with placebo, resulted in significantly greater suppression of HIV-1 and greater increases in CD4 cell counts at 48 weeks in previously treated patients with R5 HIV-1 who were receiving OBT. (ClinicalTrials.gov numbers, NCT00098306 and NCT00098722.)
Related Papers
- → Maraviroc: Pharmacokinetics and drug Interactions(2009)118 cited
- → Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability(2022)5 cited
- CCR5 antagonists in the treatment of treatment-experienced patients infected with CCR5 tropic HIV-1.(2007)
- → Reduced Frequencies and Activation of Regulatory T Cells After the Treatment of HIV-1-Infected Individuals with the CCR5 Antagonist Maraviroc Are Associated with a Reduction in Viral Loads Rather Than a Direct Effect of the Drug on Regulatory T Cells(2016)1 cited
- Pharmacology and clinical evaluation of maraviroc,a CCR5 antagonist(2008)